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Abstract Nicotine, the main component of tobacco smoke,
exerts influence on mood, and contributes to physical and
psychological dependence. Taking into account frequent con-
comitance of nicotine abuse and stress, we aimed to research
behavioral and biochemical effects associated with nicotine
administration in combination with chronic unpredictable
mild stress (CUMS). Mice were submitted to the procedure
of CUMS for 4 weeks, 2 h per day. Our results revealed that
CUMS-exposed animals exhibited behavioral alteration like
anxiety disorders in the elevated plus maze (EPM) test, the
disturbances in memory in the passive avoidance (PA) test and
depressive effects in the forced swim test (FST). Moreover,
nicotine (0.05–0.5 mg/kg), after an acute or subchronic ad-
ministration decreased stress-induced depression- and
anxiety-like effect as well as memory deficit. Administration
of metyrapone (50 mg/kg), a glucocorticosteroid antagonist,
alleviated the depressive effect induced by the CUMS. The
biochemical experiments showed decreased values of the total
antioxidant status (TAS), activities of superoxide dismutase
(SOD) and glutathione peroxidase (GPx) with simultaneously
increased in malondialdehyde (MDA) concentration in mice
submitted to the CUMS. The same effects were observed after
an acute and subchronic nicotine administration within all
examined brain structures (i.e., hippocampus, cortex, and cer-
ebellum) and in the whole brain in non-stressed and stressed
mice confirming pro-oxidative effect of nicotine. Our study
contributes to the understanding of behavioral and biochemi-
cal mechanisms involved in stress-induced disorders such as
depression, anxiety and memory disturbances as well as dual
nicotine-stress interactions on the basis of the development of
nicotine dependence.
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Introduction
Stress is related to mental and neurobiological disturbances
[1] and can be described as a state of an organism character-
ized by an increase in emotional tension caused by threatening
factors. Stress can be also defined as a process by which en-
vironmental factors (i.e., stressors) disturb the balance where-
by the organism reacts to the threat. Internal stressors mostly
result from disturbances of body homeostasis, external
stressors most frequently result from functioning in particular
social conditions. Stressors can activate complex mechanisms
of mental and physiological reactions and to a large extent
affect the condition of health of an individual.
Concerning the possible mechanisms involved, the
sympathetic-adrenal system and the hypothalamus-pituitary-
adrenals axis (HPA) are mostly responsible for the response of
an organism to stress reactions [2]. The sympathetic system is
activated immediately after the occurrence of a stressor caus-
ing an activation of the adrenal medulla and secretion of cat-
echolamines, adrenaline and noradrenaline. These hormones
are responsible for stimulation of the organism (increased
blood flow to active muscles, intensified mental and phys-
ical activity, increased reaction of the circulatory system,
intense breathing) resulting in a faster reaction to a danger.
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However, secreted in great amounts for a long time, they
may disturb normal functioning of the organism and lead to
its exhaustion [3].
The HPA plays a significant role in adaptive processes to
stressful conditions [2, 3]. The effects of the HPA axis stimu-
lation appear after several hours and may last even a few days.
Activity of the HPA system is regulated by numerous neuro-
transmitter pathways, among others glutamatergic, -amino
butyric (GABA)ergic, serotoninergic, noradrenergic and cho-
linergic. The HPA axis coordinates and controls secretion of
glucocorticosteroids from the adrenal cortex to the blood [2].
Disturbances in the HPA axis functioning occur in many men-
tal diseases, such as, among others, depression and chronic
fatigue syndrome. As a result of prolonged activation of the
HPA axis, glucocorticosteroids lead to neuronal damage of the
hippocampus and frontal cortex, the structures responsible for
emotional reactions. It has been shown that a high level of
glucocorticosteroids in the blood can damage numerous do-
paminergic, glutamatergic and serotoninergic neurons and al-
so can lead to inhibition of the process of neurogenesis. All
these changes subsequently result in a reduction of the hippo-
campus and frontal cortex volumes, which is characteristic of
patients with severe depression [2, 4].
Research on pathogenesis of depression, its frequency and
serious consequences is still continued. The use of animal
models facilitates understanding of pathogenesis, etiology,
and symptomatology of depression, examination of many ge-
netic and epigenetic factors leading to this disease and
searching for new and effective strategies of its treatment
[5]. So far, numerous attempts to create animal models of
depression have been made, which enable us to focus on at
least certain aspects of the disease [6]. Models of depression
are conducted in order to put animals without depression as
closely as possible to the clinical situation.
Many different models of depression are used in the
research conducted at present, including learned helpless-
ness, forced swim test, or social defeat stress [4, 7].
However, the chronic unpredictable mild stress (CUMS)
model is the most frequently used and considered one of
the most perfect models of depression [4, 6]. Its aim is the
induction of the state of anhedonia, which is the main
symptom of depression in humans, by subjecting animals
to the action of mild stress stimuli [8, 9]. In this model,
long-term exposure of experimental animals to various
mild unpredictable stressors (i.e., restriction, inversion of
the light-darkness cycle, deprivation of water or food, wet
litter) is related to significant changes in their behavior.
The stimuli which initiate a response to stress, the
so-called stressors, usually acting for 2 to 3 weeks, are
potentially harmful to the organism and cause acute or
chronic physiological reaction to stress [10]. All the behav-
ioral changes induced in animals in this model can be re-
versed by administration of antidepressants [11].
In the first series of experiments, we aimed to evaluate the
relationship between effects of an acute or subchronic nicotine
administration and the CUMS in mice using different animal
paradigms. In the context of the present study it should be
added that, in the search for psychological sources of addic-
tion, particular attention is paid to the role of stress and some
common mechanisms of both phenomena. It has been sug-
gested that stress plays a significant role not only in the gen-
esis of addiction but also in maintenance of abstinence [12].
As such, stress is one of the main risk factors in the develop-
ment of addictions and their recurrence. For instance, it has
been found that people’s exposure to stressors increases the
number of cigarettes smoked, the urge to smoke and the vol-
ume of inhaled tobacco smoke [13, 14]. Thus, the relationship
between stress and effects of nicotine is not fully coherent and
understood. Nicotine, as the main component of tobacco
smoke, influences, through central mechanisms, the mood
and emotional tension, and also contributes to development
of physical and mental dependence. These effects, like in the
case of other addictive agents, mostly involve dopaminergic
neurons in the mesolimbic system which is a part of the re-
ward system. Cigarette smoking, involving delivery of subse-
quent amounts of nicotine, causes a subjective feeling of plea-
sure and becomes a way of dealing with stress in smokers
[15]. In certain experimental animal models, it has been dem-
onstrated that chronic and acute stress may aggravate both
behavioral as well as neuronal effects caused by administra-
tion of nicotine. The data also report that nicotine modifies the
influence of stress on anxiety behavior and cognitive process-
es [16]. Taking into consideration frequent concomitance of
nicotine abuse and stress which accompanies daily life, find-
ing actual effects of simultaneous exposure to these factors
can have great clinical and toxicological significance.
In the second series of biochemical experiments, we aimed
to describe alterations in antioxidant barrier of the brain and its
selected regions (i.e., prefrontal cortex, cerebellum and hippo-
campus) in a mouse model of CUMS with and without acute
or subchronic nicotine administration. The presence of oxida-
tive stress was validated by the level of tissue total antioxidant
status (TAS), activities of some key antioxidant enzymes, like
superoxide dismutase (SOD) and glutathione peroxidase
(GPx) as well as concentration of malondialdehyde (MDA),
the main product of lipid peroxidation.
In this context, it has been suggested that up-regulation of
the stress hormones, induced by hyperactivation of HPA axis,
may induce oxidative stress with the overproduction of reac-
tive oxygen species (ROS) [17]. First of all, cortisol increases
oxygen supply to target tissues (including brain) by increasing
blood pressure and heart rate. Therefore more oxygen, which
is delivered to all tissues, exerts more deleterious effects with-
in cells. Brain is particularly vulnerable to oxidative stress.
Weighting 2 % of total body mass it consumes over 20 % of
oxygen used by the whole organism. Moreover, it consists of
abundant polyunsaturated fatty acids that are substrates for
ROS [18], and compounds easily undergoing redox reactions
like iron ions or ascorbic acid [19]. Secondly, cortisol disturbs
electron transport chain by destroying enzymes constituents of
certain mitochondrial enzyme complex activities (NADH de-
hydrogenase—complex I, succinate dehydrogenase—com-
plex II, cytochrome c reductase—complex III, cytochrome c
oxidase—complex IV) and causing electron leakage. These
phenomena liberate free electrons that form reactive species
with neutral molecules. Although free radicals at physiologi-
cal concentrations exert important functions in proper cell
functioning, their increased amount may disturb main cellular
processes. All cells have special emergency system, which is
activated in case of increased free radicals level. The so-called
antioxidant barrier consists of two systems: enzymatic and
non-enzymatic ones. Antioxidant enzymes cooperate with
each other to inhibit excessive production of ROS and to pro-
tect against their harmful action. SOD, a key antioxidant en-
zyme, catalyzes the reaction of superoxide anion radical (O-2)
dismutation into oxygen and hydrogen peroxide. Then reduc-
tion of hydrogen peroxide to oxygen and water can occur in
two different ways with participation of two different en-
zymes: GPx and catalase (CAT). GPx catalyzes the reaction
with expense of glutathione, which is used as electron donor
to regenerate the enzyme [20]. Non-enzymatic antioxidant
barrier constituents, e.g., ascorbate, coenzyme Q10, vitamin
E, and glutathione, are radical scavengers. They directly react
with free radicals and detoxify them by removing their radical
character throughout electron donation [21]. As the organism
developed numerous mechanisms to protect oxidative ho-
meostasis, some internal or external conditions (in form of
acute or chronic stimuli) may disturb the equilibrium, caus-
ing oxidative stress. In such a situation, ROS attack main
cellular constituents, like DNA, proteins or lipids, to de-
stroy them. Oxidative stress induces lipid peroxidation,
which destabilizes membranes and may cause cell death
in every brain region [17]. The level of lipids peroxidation
can be monitored by the concentration of the end product
of the process, i.e., MDA level.
In total, both series of our complementary experiments for
the first time aimed to evaluate behavioral and biochemical
impact and complex relationship between nicotine and the




All experiments were conducted according to the National
Institute of Health Guidelines for the Care and Use of
Laboratory Animals and to the European Community
Council Directive for the Care and Use of Laboratory
Animals of 24 November 1986 (86/609/EEC). The protocol
was approved by the Committee on the Ethics of Animal
Experiments of the Medical University of Lublin (Permit
Number: 43/2013). All efforts were made to minimize animal
suffering and to reduce the number of animals used.
Animals
The experiments were carried out on naive male Swiss mice
(Farm of Laboratory Animals, Warsaw, Poland) weighing 20–
25 g at the beginning of the experiments. The animals were
maintained under standard laboratory conditions (12 h light/
dark cycle, room temperature 21±1 °C) with free access to tap
water and laboratory chow (Agropol, Pulawy, Poland) and
were adapted to the laboratory conditions for at least 1 week.
Each experimental group consisted of 8–12 animals. Different
mice were used for each drug and time treatment.
Drugs
Experimental Protocols
Mice subjected to the CUMS procedure (further described in
details) were called as stressed mice. Unstressed mice were
exposed to behavioral tests, and not subjected to the CUMS.
Nicotine was administered 30 min before behavioral test and/
or chronically 30 min before CUMS procedure to stressed as
well as to unstressed control mice. Metyrapone was adminis-
tered 60 min before behavioral tests. Behavioral testing was
done in independent groups of mice on the 28th day.
At the beginning of the experiments, mice were randomly
divided into different groups (8–12 mice in each group).
Group I consisted of unstressed control and saline/nicotine/
metyrapone administered mice (acutely, on the 28th day);
group II comprised unstressed control mice administered sa-
line or nicotine subchronically (once a day, on the 15–27th
day and on the test day); group III consisted of stressed control
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The following compounds were tested: (−) nicotine hydrogen
tartrate (0.05, 0.1, 0.2 and 0.5 mg/kg, Sigma-Aldrich, St.
Louis, MO, USA), and metyrapone (50 mg/kg, Tocris
Bioscience, UK). Drugs were dissolved in saline solution
(0.9 % NaCl). Nicotine was administered subcutaneously (s.
c.) whereas metyrapone was administered intraperitoneally (i.
p.) at a volume of 10 ml/kg. Drug doses refer to the salt form.
The pH of the nicotine solution was adjusted to 7.0. Fresh
drug solutions were prepared on each day of experimentation.
Control groups received saline injections of the same volume
and via the same route of administration.
The range of doses of drugs was chosen based on literature
data [22, 23], our recently published articles [21, 24] and
preliminary studies.
and saline/nicotine/metyrapone administered mice (acutely,
on the 28th day); group IV consisted of stressed
control mice administered saline or nicotine subchronically
(once a day, on the 15–27th day and on the test day).
CUMS Procedure
The CUMS protocol was performed as described previously
[8, 25, 26] with minor modifications. In brief, mice were sub-
jected to different kinds of mild stressors, which varied from
day to day to make the stress procedure unpredictable. These
stressors were randomly scheduled over a 1-week period and
repeated throughout the 4 weeks experiment for 2 hs daily.
There were a total of seven stressors: (1) lack of litter; (2) cage
shaking; (3) lights on overnight; (4) damp sawdust overnight;
(5) food deprivation overnight; (6) an electric buzzer, 90 dB
for 5 min; (7) tilted cage at 45°. Non-stressed mice were left
undisturbed in their home cages. Twenty-four hours after the
end of the CUMS protocol, all animals were exposed to one of
the behavioral paradigms described below.
Forced Swim Test
The forced swim test (FST) was as described by Porsolt et al.
[7]. In brief, each mouse was placed individually in a glass
cylinder (height 25 cm, diameter 10 cm) containing 10 cm of
water at 23–25 °C. Mice were placed in the water and forced
to swim for 6 min. The duration of immobility was recorded
during the last 4 min of the 6 min test. A mouse was consid-
ered to be immobile when it stopped struggling and passively
moved to remain floating and keep its head above water.
Water was changed between trials and temperature was main-
tained at 23–25 °C. Immediately after the test, mice were
covered by a dry towel and then placed under a heating lamp
until they were dry.
Elevated Plus Maze Test
The experimental apparatus was shaped like a plus sign and
consisted of a central platform (5 × 5 cm), two open arms
(30 × 5 cm) opposite to each other and two equal-sized
enclosed (30×5×15 cm) arms opposite to each other. The
maze was made of dark Plexiglas, elevated to a height of
50 cm above the floor and illuminated by a dim light.
The used procedure was chosen based on our recently pub-
lished data [21, 24] and to the method of Lister [27].
Anxiolytic activity was indicated by an increase in time spent
on the open arms or in number of entries to the open arms;
anxiogenic effects were characterized by a decrease in those
measures. The percentage of time spent on the open arms was
calculated, just as was the percentage of entries into the open
arm. Additionally, the number of enclosed arm entries was
recorded as the indicator of motor activity of tested animals.
Passive Avoidance Test
In the subsequent trial (retention) 24 h later, the same
mouse was again placed individually in the light compartment
of the apparatus and the time taken to re-enter the dark com-
partment was recorded (TL2). No foot-shock was applied in
this trial. The experimental procedure involved examination
of memory acquisition (the animals received injections of the
substance before pre-test) [28, 29].
It should be noted that doses of nicotine, i.e., active dose
causing an antidepressant effect in the FST, inactive dose in
the elevated plus maze (EPM) and procognitive dose (after an
acute administration) in the passive avoidance (PA) test have
been chosen according to the literature data and our previous
experiments [21, 24, 29–31]. For subchronic injections, doses
of nicotine have been slightly lower as compared to those
administered acutely.
Collection of Tissues
Immediately after the behavioral tests, mice were sacrificed by
decapitation and the whole brain was carefully taken out and
rinsed in ice-cold saline to remove blood. The cerebellum,
cerebral cortex, and hippocampus were rapidly dissected.
The whole brain as well as isolated structures was used for
the study.
Preparation of Brain Homogenates
The collected tissues were homogenized in 10:1 (vol:wt)
chilled Tris buffer (pH 7.4) on ice for 20 s and centrifuged
at 10000 g for 10 min at 4 °C to separate nuclear debris.
The supernatant was collected and used for further study.
TAS, activity of SOD and GPx as well as MDA level were
determined from these supernatants spectrophotometrical-
ly with use of HITACHI 2800 apparatus and microplate
reader EPOCH.
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The apparatus and used procedure was described in detail in
our previous article [21]. The apparatus consisted of
two-compartment acrylic box with a lighted and darkened
one. The light chamber was illuminated by a fluorescent light
(8W) and connected to the dark chamber which was equipped
with an electric grid floor. Entrance of animals to the dark box
was punished by an electric foot-shock (0.2 mA for 2 s). On
the 1st day of training (pre-test), mice were placed individu-
ally into the light compartment and allowed to explore the
light box. After 30 s, the guillotine door was raised to allow
the mice enter the dark compartment. When the mice entered
this dark compartment, the guillotine door was closed and an
electric foot-shock (0.2 mA) of 2 s duration was immediately
delivered. The latency time for entering the dark compartment
was recorded (TL1).
908 Mol Neurobiol (2017) 54:904–921
Determination of MDA Concentration
Lipid peroxidation was analyzed by determination of MDA
concentration using thiobarbituric acid (TBA) reaction [32].
Briefly, 0.5 ml of tissue homogenate supernatant was mixed
with 2.5 ml 1.22 M TCA in 0.6 M HCl and allowed to stand
for 15 min. Then 1.5 ml of 0.9 % TBA was added and the
mixture was incubated for 30 min in a boiling water bath.
After cooling, 4 ml of n-butanol was added and the mixture
was shaken variously. The samples were centrifuged at
1500×g for 10 min and then the absorbance of organic phase
was measured at 532 nm with respect to blank (n-butanol
alone). The concentration of MDAwas read from the standard
curve obtained by using malonaldehyde bis-dimethylacetal
and expressed as μM of MDA/g of wet tissue.
Determination of TAS
TAS of brain homogenates was determined with
ready-to-use diagnostic kit TAS by RANDOX (Randox
Laboratories Ltd., UK). The method assumes that ABTS®
(2,2′-Azino-di-[3-ethylbenzthiazoline sulphonate]) produce a
radical cation ABTS®*+ when incubated with a peroxidase
(metmyoglobin) and H2O2. The radical cation has a relatively
stable blue-green color, however its production can be sup-
pressed by the addition of antioxidants present in the exam-
ined samples. Changes in absorption measured at 600 nm are
proportional to the antioxidant concentration in the tissues
homogenates. Results are expressed in mmol/l tissue.
Determination of SOD Activity
The activity of SOD was measured with the use of
ready-to-use diagnostic kits RANSOD by Randox. The meth-
od employs xantine and xantine oxidase (XOD) to generate
superoxide radicals, which react with iodonitrotetrazolium
chloride to form red formazan dye. The superoxide dismutase
activity is then measured by the degree of inhibition of the
reaction. The increase in absorbance at 505 nm is read. Results
are expressed in U/g protein.
Determination of GPx Activity
The activity of GPx was measured with the use of
ready-to-use diagnostic kits RANSEL by Randox. This meth-
od is based on that of Paglia and Valentine [33]. GPx catalyzed
the oxidation of glutathione (GSH) by cumene hydroperoxide.
In the presence of glutathione reductase (GR) and NADPH,
the oxidized glutathione (GSSG) is immediately converted to
the reduced form with a concomitant oxidation of NADPH to
NADP+. The decrease in absorbance at 340 nm is measured.
Results are expressed in U/g protein.
Determination of Protein Content
The protein content was determined by the Bradford method
[34] using BSA as the standard.
Statistical Analysis
The data were expressed as the means± standard error of the
mean (SEM). The statistical analyses were performed by the
one-way and two-way analysis of variance (ANOVA). Post
hoc comparison of means was carried out with the Tukey’s
test for multiple comparisons, when appropriate. The confi-
dence limit of P<0.05 was considered statistically significant.
For the memory-related responses, the changes in PA per-
formance were expressed as the difference between retention
and training latencies and were taken as a latency index (IL).
IL was calculated for each animal and reports as the ratio:
IL ¼ TL2−TL1ð Þ=TL1
TL1—the time taken to enter the dark compartment during
the training
TL2—the time taken to re-enter the dark compartment dur-
ing the retention test.
All statistical tests were performed using GraphPad Prism
version 5.01 for Windows (GraphPad Software, USA).
Results
Depression-like Behavior in Unstressed and StressedMice
in the FST; Effects of Nicotine and Metyrapone
Figure 1 describes the effect of an acute administration of
nicotine in stressed (i.e., subjected to the CUMS protocol)
and unstressed mice in the FST (two-way ANOVA: condition
effect [F(1,41)=11.05, P=0.0019], treatment effect [F(1,41)
=25.01,P<0.0001] without interaction effect [F(1,41)=1.41,
P=0.3133]). A post hoc analysis showed that the exposition
to the CUMS protocol increased immobility time in stressed
mice as compared to unstressed control (P < 0.05).
Furthermore, an acute treatment with nicotine (0.2 mg/kg)
significantly decreased the immobility duration of stressed
mice as compared with the stressed saline-treated group
(P< 0.01). Nicotine also significantly reduced duration of
swimming in unstressedmice as comparedwith the unstressed
saline-treated group (P<0.05).
Figure 2 shows the effect of a subchronic administration of
nicotine in stressed and unstressed mice in the FST (two-way
ANOVA: condition effect [F(1,37)=16.46, P=0.0002], treat-
ment effect [F(1,37)=17.58, P=0.0002] without interaction
effect [F(1,37)=0.01, P=0.9420]). A post hoc analysis fur-
ther confirmed that the exposition to the CUMS protocol
Anxiety-like Behavior in Unstressed and Stressed Mice
in the EMP; Effects of Nicotine
Figure 4 presents the effect of an acute administration of nic-
otine in stressed (i.e., subjected to the CUMS protocol) and
unstressed mice on the percentage of time spent on the open
arms (two-way ANOVA: treatment effect [F(1,26) = 81.47,
P<0.0001], interaction effect [F(1,26) = 33.23, P<0.0001]
without condition effect [F(1,26)=0.06, P=0.8017]) as well
as the percentage of open arm entries (two-way ANOVA:
condition effect [F(1,36)=11.47, P=0.0017], treatment effect
[F(1,36) = 235.48, P<0.0001] and interaction effects [F(1,
36)=278.49, P<0.0001]). A post hoc analysis showed that
the exposition to the CUMSprotocol decreased the percentage
of time spent on the open arms (Fig. 4a) and the percentage of
open arm entries (Fig. 4b) in stressed mice as compared with
unstressed control (P<0.05). Furthermore, an acute treatment
with nicotine (0.5 mg/kg) significantly increased both values
in nicotine-treated stressed mice as compared with the control
saline-treated group (P<0.001) (Fig. 4a, b). The percentage of
open arm entries was also increased in nicotine-treated
stressedmice as compared with the nicotine-treated unstressed




























Fig. 2 Effect of nicotine administered subchronically (day 15–27) in
unstressed and stressed mice subjected to the CUMS in the FST.
Nicotine (0.1 mg/kg) was administered s.c. 30 min before the CUMS
procedure as well as to unstressed control mice and additionally 30 min
before the FST (day 28). The values represent the mean ± SEM (n= 8–12
mice per group). *P< 0.05 vs. unstressed, saline-treated group, &P< 0.05
vs. stressed, saline-treated group; ^P < 0.05 vs. unstressed, nicotine-



























Fig. 3 Effect of metyrapone in unstressed and stressed mice subjected to
the CUMS in the FST. Metyrapone (50 mg/kg) was administered i.p.
60 min before the test. The values represent the mean ± SEM (n = 8–12
mice per group). **P < 0.01 vs. unstressed, saline-treated group;
&&&P < 0.001 vs. stressed, saline-treated group; ^^^P < 0.001 vs.


























Fig. 1 Effect of nicotine administered acutely in unstressed and stressed
mice subjected to the CUMS in the FST. Nicotine (0.2 mg/kg) was
administered s.c. 30 min before the test. The values represent the mean
± SEM (n= 8–12mice per group). *P< 0.05 vs. unstressed, saline-treated
group; &&P< 0.01 vs. stressed, saline-treated group (Tukey’s post hoc
test)
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increased immobility time in stressed mice as compared with
unstressed control (P<0.05). Furthermore, repeated treatment
with nicotine (0.1 mg/kg) significantly changed the immobil-
ity duration of stressed mice as compared to the stressed
saline-treated group (P<0.05) and with unstressed mice, after
subchronic nicotine treatment (P<0.05). Nicotine also signif-
icantly reduced duration of swimming in unstressed mice as
compared with the unstressed saline-treated group (P<0.05).
Figure 3 presents the effect of an acute administration of
metyrapone in stressed and unstressed mice in the FST
(two-way ANOVA: treatment effect [F(1,41) = 73.40,
P < 0.0001] and interaction effect [F(1,41) = 385.53,
P < 0.0001] without condition effect [F(1,41) = 1.42,
P=0.2398]). A post hoc analysis further confirmed that the
exposition to the CUMS protocol increased immobility time
in stressed mice as compared with unstressed control
(P<0.01). Furthermore, an acute treatment with metyrapone
(50 mg/kg) significantly decreased the immobility duration of
stressed mice as compared with stressed, saline-treated group

















































Fig. 5 Effect of nicotine administered subchronically (day 15–27) in
unstressed and stressed mice subjected to the CUMS on percentage of
time spent in open arms (a) and percentage of open arm entries (b) in the
EPM test. Nicotine (0.1 mg/kg) was administered s.c. 30 min before the
CUMS procedure as well as to unstressed control mice and additionally
30 min before the EPM (day 28). The values represent the mean ± SEM
(n = 8–12 mice per group). **P < 0.01 vs. unstressed, saline-treated
group; &&P < 0.01 and &&&P < 0.001 vs. stressed, saline-treated
















































Fig. 4 Effect of nicotine administered acutely in unstressed and stressed
mice subjected to the CUMS on percentage of time spent in open arms (a)
and percentage of open arm entries (b) in the EPM test. Nicotine
(0.5 mg/kg) was administered s.c. 30 min before the test. The values
represent the mean ± SEM (n = 8–12 mice per group). *P < 0.05 vs.
unstressed, saline-treated group; &&&P < 0.001 vs. stressed, saline-
treated group; ^^P < 0.01 vs. unstressed, nicotine-treated group
(Tukey’s post hoc test)
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on anxiety-like behaviors in nicotine-treated (0.5 mg/kg) un-
stressed mice.
Figure 5 shows the effect of a subchronic administration of
nicotine in stressed and unstressed mice on the percentage of
time spent on the open arms (two-way ANOVA: condition
effect [F(1,40) = 27.72, P<0.0001], treatment effect [F(1,
40) = 20.16, P < 0.0001], with interaction effect [F(1,40)
=161.58, P<0.0001]) as well as the percentage of open arm
entries (two-way ANOVA: condition effect [F(1,41)=103.72,
P<0.0001], treatment effect [F(1,41) = 102.39, P<0.0001]
with interaction effect [F(1,41)=69.13, P<0.0001]). A post
hoc analysis showed that the exposition to the CUMS protocol
decreased the percentage of time spent on the open arms
(Fig. 5a) and the percentage of open arm entries (Fig. 5b) in
stressed mice as compared with unstressed control (P<0.01).
Furthermore, subchronic treatment with nicotine (0.1 mg/kg)
significantly increased the time spent on the open arms
(P<0.01) (Fig. 5a) and the percentage of open arm entries
(P < 0.001) (Fig. 5b) in nicotine-treated stressed mice as
compared with the control saline-treated group. However,
there was no influence on anxiety-like behavior in
nicotine-treated (0.1 mg/kg) unstressed mice.
Moreover, the CUMS protocol as well as an acute or sub-
chronic nicotine injection to stressed and unstressed mice did
not provoke any changes in number of enclosed arm entries in
the EPM, thus causing no changes in the locomotor activity of
animals (P>0.05, post hoc Tukey’s test) (Table 1).
Memory-Related Behavior in Unstressed and Stressed
Mice in the PATask; Effects of Nicotine
Figure 6 presents the effect of an acute administration of nic-
otine in stressed (i.e., subjected to the CUMS protocol) and
unstressed mice in the PA task (two-way ANOVA: condition
effect [F(1,35) = 34.47, P < 0.0001], treatment effect
[F(1,35) = 198.38, P < 0.0001] without interaction effect
Table 1 Mean number (± SEM) of enclosed arms entries in the EPM test in stressed or unstressed mice treated acutely (A) or chronically (B) with
nicotine; n= 8–12
A
Treatment CUMS Unstressed control CUMS+ nicotine 0.5 mg/kg (day 28) Control + nicotine 0.5 mg/kg (day 28)
The number of enclosed
arms entries
10.600 ± 1.087 8.500 ± 1.493 10.130± 0.581 8.286 ± 0.918
B
Treatment CUMS Unstressed control CUMS+ nicotine 0.1 mg/kg
(day 14–27)
Control + nicotine 0.1 mg/kg
(day 14–27)
The number of enclosed
arms entries






























Fig. 6 Effect of nicotine administered acutely in unstressed and stressed
mice subjected to the CUMS in the PA task. Nicotine (0.5 mg/kg) was
administered s.c. 30 min before the pre-test. The values represent the
mean ± SEM (n = 8–12 mice per group). *P < 0.05 vs. unstressed,
saline-treated group; &&P < 0.01 vs. stressed, saline-treated group

























Fig. 7 Effect of nicotine administered subchronically (day 15–27) in
unstressed and stressed mice subjected to the CUMS in the PA task.
Nicotine (0.05 mg/kg) was administered s.c. 30 min before the CUMS
procedure as well as to unstressed control mice and 30 min before the PA
test (day 28). The values represent the mean ± SEM (n= 8–12 mice per
group). *P < 0.05 vs. unstressed, saline-treated group; &&P< 0.01 vs.
stressed, saline-treated group (Tukey’s post hoc test)
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[F(1,35) = 1.41, P= 0.2423]). A post hoc analysis showed
that the exposition to the CUMS protocol decreased IL
value in stressed mice as compared with unstressed control
(P< 0.05). Furthermore, an acute treatment with nicotine
(0.5 mg/kg) significantly increased IL value in stressed
mice as compared with the stressed saline-treated group
(P< 0.01). Nicotine also significantly increased IL value
in unstressed mice as compared with unstressed
saline-treated group (P<0.05).
Figure 7 shows the effect of a subchronic administration of
nicotine in stressed and unstressed mice in the PA task
(two-way ANOVA: treatment effect [F(1,38) = 39.23,
P<0.0001], interaction effect [F(1,38) =99.22, P<0.0001],
without condition effect [F(1,38)=0.00, P=0.9889]). A post
hoc analysis showed that the exposition to the CUMS protocol
decreased IL value in stressed mice as compared with un-
stressed control (P<0.05). Furthermore, subchronic treatment
with nicotine (0.05 mg/kg) significantly increased IL value in
stressed mice as compared with the stressed saline-treated
group (P<0.01). However, there was no influence of nicotine
treatment on IL value in unstressed mice.
Oxidative Stress Biomarkers in Brain and its Particular
Structures in Unstressed and Stressed Mice; Effects
of Nicotine
Table 2 shows effects of the CUMS and an acute administra-
tion of nicotine in stressed and unstressed mice on chosen
markers of oxidative stress. Data are presented for TAS: in
the whole brain (two-way ANOVA: condition effect [F(3,
72) = 16.57, P<0.0001], treatment effect [F(1,72) = 32.48,
P < 0.0001] without interaction effect [F(3,72) = 0.41,
P= 0.7494]) as well as in single structures as cerebellum
(two-way ANOVA: condition effect [F(3,72) = 31.01,
P<0.0001], treatment effect [F(1,72) = 217.67, P<0.0001]
without interaction effect [F(3,72)=0.51, P=0.6800]), hippo-
campus (two-way ANOVA: condition effect [F(3,72)=14.84,
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without interaction effect [F(3,72) =1.70, P=0.1754]), and
cortex (two-way ANOVA: condition effect [F(3,72)=17.67,
P< 0.0001], treatment effect [F(1,72) = 20.62, P< 0.0001]
without interaction effect [F(1,72) = 0.31, P = 0.8179]);
SOD: in the whole brain (two-way ANOVA: condition effect
[F(3,72) = 36.84, P < 0.0001], treatment effect [F(1,72)
=201.13, P<0.0001] with interaction effect [F(3,72)=4.08,
P= 0.0098]) as well as in single structures as cerebellum
(two-way ANOVA: condition effect [F(3,72) = 25.12,
P<0.0001], treatment effect [F(1,72) = 113.13, P<0.0001]
without interaction effect [F(3,72)=1.47, P=0.2298]), hippo-
campus (two-way ANOVA: condition effect [F(3,72)=43.20,
P<0.0001], treatment effect [F(1,72) = 252.45, P<0.0001]
with interaction effect [F(3,72)=6.19, P=0.0008]), and cor-
tex (two-way ANOVA: condition effect [F(3,72) = 30.23,
P<0.0001], treatment effect [F(1,72) = 316.74, P<0.0001]
with interaction effect [F(1,72)=12.58, P<0.0001]); GPx in
the whole brain (two-way ANOVA: condition effect [F(3,72)
= 37.59, P < 0.0001], treatment effect [F(1,72) = 321.08,
P < 0.0001] with interaction effect [F(3,72) = 8.33,
P< 0.0001]) as well as in single structures as cerebellum
(two-way ANOVA: condition effect [F(3,72) = 43.29,
P<0.0001], treatment effect [F(1,72) = 927.89, P<0.0001]
with interaction effect [F(3,72) = 8.11, P<0.0001]), hippo-
campus (two-way ANOVA: condition effect [F(3,72)=7.49,
P=0.0002], treatment effect [F(1,72) = 198.87, P<0.0001]
with interaction effect [F(3,72)=3.30, P=0.0250]), and cor-
tex (two-way ANOVA: condition effect [F(3,72) = 34.19,
P<0.0001], treatment effect [F(1,72) = 430.41, P<0.0001]
without interaction effect [F(1,72) = 1.61, P = 0.1946]);
MDA in the whole brain (two-way ANOVA: condition effect
[F(3,72) = 26.23, P < 0.0001], treatment effect [F(1,72)
= 114.85, P< 0.0001] without interaction effect [F(3,72)
=0.50, P=0.6839]) as well as in single structures as cerebel-
lum (two-way ANOVA: condition effect [F(3,72) = 12.79,
P=0.0001], treatment effect [F(1,72) = 479.98, P<0.0001]
without interaction effect [F(3,72)=0.75, P=0.5268]), hippo-
campus (two-way ANOVA: condition effect [F(3,72)=16.17,
P<0.0001], treatment effect [F(1,72) = 278.13, P<0.0001]
without interaction effect [F(3,72) = 3.12, P=0.0311]), and
cortex (two-way ANOVA: condition effect [F(3,72)=17.05,
P< 0.0001], treatment effect [F(1,72) = 17.03, P< 0.0001]
without interaction effect [F(1,72)=1.24, P=0.3002]).
A post hoc analysis showed that the exposition to the
CUMS protocol decreased the values of TAS (whole brain
P<0.01, cerebellum P<0.001, hippocampus P<0.01), activ-
ities of SOD (whole brain P<0.001, cerebellum P<0.01, hip-
pocampus P<0.001, cortex P<0.001) and GPx (whole brain
P< 0.001, cerebellum P < 0.001, hippocampus P < 0.001,
cortex P<0.001) with simultaneous increased in MDA con-
centrations (whole brain P<0.001, cerebellum P<0.001, hip-
pocampus P<0.001, cortex P<0.01) in stressed mice as com-
pared with unstressed control.
Additionally, nicotine (0.5 mg/kg) decreased TAS value in
stressed mice in the whole brain (P < 0.01), cerebellum
(P < 0.001), hippocampus (P < 0.05), cortex (P < 0.001),
whereas nicotine at the dose of 0.2 mg/kg decreased TAS
value only in the hippocampus (P<0.05) as compared with
the stressed saline-treated group. Furthermore, in unstressed
mice an acute treatment with 0.2 mg/kg of nicotine signifi-
cantly increased TAS value in the cerebellum (P<0.001) and
hippocampus (P<0.05), and after 0.5 mg/kg in the whole
brain and all examined structures (P<0.001) as compared
with unstressed saline-treated group.
Moreover, significant decrease in SOD and GPx activity in
the whole brain and all examined structures was observed in
stressed mice receiving 0.5 mg/kg of nicotine in case of SOD
(whole brain P<0.01, cerebellum P<0.001, hippocampus
P < 0.001) and GPx (whole brain P < 0.01, cerebellum
P < 0.001, cortex P < 0.001) in comparison with stressed
saline-treated group. Whereas, nicotine at the dose of
0.2 mg/kg decreased SOD value only in the cerebellum
(P<0.01) and hippocampus (P<0.05) as well as decreased
GPx value in the cortex (P< 0.01) as compared with the
stressed saline-treated group. Also, nicotine administered at
the dose of 0.1 mg/kg decreased SOD value in the cerebellum
(P<0.05). In unstressed mice receiving 0.5 mg/kg of nicotine,
significant dose-dependent decrease in antioxidant enzymes
activity (SOD and GPx) in the whole brain and all examined
structures was observed in case of SOD (P<0.001) and GPx
(P<0.001) in comparison to unstressed saline-treated group.
Whereas, nicotine at the dose of 0.2 mg/kg decreased SOD
value only in the hippocampus and cortex (P<0.001) as well
as decreased GPx value (whole brain P<0.001, cerebellum
P<0.001, hippocampus P<0.05, cortex P<0.001) as com-
pared with the unstressed saline-treated group. Also, nicotine
administered at the dose of 0.1 mg/kg decreased GPx value
only in the cerebellum (P<0.05).
The procedure of CUMS caused statistically significant
increase in MDA concentration in stressed mice in com-
parison to unstressed control group (whole brain P< 0.001,
cerebellum P < 0.001, hippocampus P < 0.001, cortex
P< 0.01). Moreover, nicotine at the dose of 0.2 mg/kg in-
creased MDA value in the whole brain (P< 0.05) and cor-
tex (P < 0.001) as compared with the unstressed
saline-treated group. Also, nicotine administered at the
dose of 0.1 mg/kg increased MDA value only in the cortex
(P< 0.05). The stressed animals, receiving the highest dose
of nicotine (0.5 mg/kg) exhibited significant increase in
MDA concentration in the whole brain (P < 0.001) and
cortex (P< 0.01) in comparison to stressed saline group.
The increase in MDA level in unstressed mice receiving
nicotine at the dose of 0.5 mg/kg (whole brain P< 0.001,
cerebellum P < 0.05, hippocampus P < 0.001, cortex
P< 0.001) in comparison to unstressed saline group was
also observed.
Table 3 further presents effects of the CUMS and also a
subchronic administration of nicotine in stressed and un-
stressed mice on chosen markers of oxidative stress. Data
are presented for TAS: in the whole brain (two-way
ANOVA: condition effect [F(3,72)=12.81, P<0.0001], treat-
ment effect [F(1,72)=52.28, P<0.0001] without interaction
effect [F(3,72)=0.47, P=0.7071]) as well as in single struc-
tures as cerebellum (two-way ANOVA: condition effect [F(3,
72) = 4.86, P= 0.0039], treatment effect [F(1,72) = 85.45,
P < 0.0001] without interaction effect [F(3,72) = 0.04,
P=0.9902]), hippocampus (two-way ANOVA: condition ef-
fect [F(3,72) =13.50, P<0.0001], treatment effect [F(1,72)
= 43.92, P < 0.0001] without interaction effect [F(3,72)
=0.32, P=0.8111]), and cortex (two-way ANOVA: condition
effect [F(3,72)=11.89, P<0.0001], treatment effect [F(1,72)
=24.13,P<0.0001] without interaction effect [F(1,72)=0.77,
P=0.5166]); SOD: in the whole brain (two-way ANOVA:
condition effect [F(3,72)=16.86, P<0.0001], treatment effect
[F(1,72)=156.28, P<0.0001] without interaction effect [F(3,
72)=1.49, P=0.2239]) as well as in single structures as cer-
ebellum (two-way ANOVA: condition effect [F(3,72)=13.64,
P< 0.0001], treatment effect [F(1,72) = 76.08, P< 0.0001]
without interaction effect [F(3,72)=1.12, P=0.3477]), hippo-
campus (two-way ANOVA: condition effect [F(3,72)=26.98,
P<0.0001], treatment effect [F(1,72) = 206.00, P<0.0001]
with interaction effect [F(3,72)=7.49, P=0.0002]), and cor-
tex (two-way ANOVA: condition effect [F(3,72) = 23.41,
P<0.0001], treatment effect [F(1,72) = 222.95, P<0.0001]
with interaction effect [F(1,72)=6.45, P=0.0006]); GPx in
the whole brain (two-way ANOVA: condition effect [F(3,
72)=16.41, P<0.0001], treatment effect [F(1,72)= 482.20,
P < 0.0001] with interaction effect [F(3,72) = 3.00,
P= 0.0360]) as well as in single structures as cerebellum
(two-way ANOVA: condition effect [F(3,72) = 53.77,
P<0.0001], treatment effect [F(1,72)=1226.01, P<0.0001]
with interaction effect [F(3,72)=13.30, P<0.0001]), hippo-
campus (two-way ANOVA: condition effect [F(3,72)=9.96,
P<0.0001], treatment effect [F(1,72) = 360.13, P<0.0001]
with interaction effect [F(3,72)=2.80, P=0.0460]), and cor-
tex (two-way ANOVA: condition effect [F(3,72) = 37.62,
P<0.0001], treatment effect [F(1,72) = 709.90, P<0.0001]
with interaction effect [F(1,72) =10.44, P<0.0001]); MDA
in the whole brain (two-way ANOVA: condition effect [F(3,
72)=19.10, P<0.0001], treatment effect [F(1,72)= 161.52,
P < 0.0001] without interaction effect [F(3,72) = 0.18,
P= 0.9121]) as well as in single structures as cerebellum
(two-way ANOVA: condition effect [F(3,72) = 7.93,
P=0.0001], treatment effect [F(1,72) = 602.74, P<0.0001]
without interaction effect [F(3,72)=1.88, P=0.1398]), hippo-
campus (two-way ANOVA: condition effect [F(3,72)=33.00,
P< 0.0001], treatment effect [F(1,72) = 36.13, P< 0.0001]
without interaction effect [F(3,72) =1.20, P=0.3163]), and
cortex (two-way ANOVA: condition effect [F(3,72)=18.40,
P< 0.0001], treatment effect [F(1,72) = 16.05, P< 0.0001]
without interaction effect [F(1,72)=1.63, P=0.1888]).
A post hoc analysis showed that the exposition to the
CUMS protocol decreased the values of TAS (whole brain
P<0.01, cerebellum P<0.001, hippocampus P<0.05, cortex
P<0.05), activities of SOD (whole brain P<0.001, cerebel-
lum P<0.001, hippocampus P<0.001, cortex P<0.001) and
GPx (whole brain P<0.001, cerebellum P<0.001, hippocam-
pus P<0.001, cortex P<0.001) with simultaneous increased
in MDA concentrations (whole brain P<0.001, cerebellum
P<0.001, hippocampus P<0.01, cortex P<0.01) in stressed
mice as compared with unstressed control. Furthermore, sub-
chronic treatment with 0.5 mg/kg of nicotine significantly
increased TAS value in the whole brain (P<0.001), hippo-
campus (P<0.001), cortex (P<0.001) in unstressed mice as
compared with unstressed saline-treated group. Moreover,
nicotine (0.5 mg/kg) decreased TAS value in the whole brain
(P<0.05), and hippocampus (P<0.01) as compared with the
stressed saline-treated group.
In stressed mice, significant decrease in antioxidant en-
zymes activity in animals receiving 0.5 mg/kg of nicotine
was observed in case of SOD (whole brain P<0.05) and
GPx (cerebellum P<0.001, cortex P<0.05) in comparison
to stressed saline-treated group, whereas nicotine at the dose
of 0.1 mg/kg decreased GPx value (cerebellum P<0.01) as
compared with the stressed saline-treated group. Significant
dose-dependent decrease in antioxidant enzymes activity
(SOD and GPx) in the whole brain and all examined structures
was also observed in unstressed mice receiving chronically
0.5 mg/kg of nicotine in case of SOD (P< 0.001) and in
GPx (P<0.001) in comparison to unstressed saline-treated
group. Whereas, in these mice nicotine at the dose of
0.1 mg/kg decreased SOD value in the whole brain
(P<0.05), cerebellum (P<0.01), hippocampus (P<0.001),
cortex (P<0.001) as well as decreased GPx value in the whole
brain (P < 0.001), cerebellum (P < 0.001), hippocampus
(P<0.05), cortex (P<0.001) as compared with the unstressed
saline-treated group. Also, nicotine administered at the dose of
0.05 mg/kg decreased SOD activity in the hippocampus
(P<0.05) and GPx activity in the cerebellum (P<0.001), hip-
pocampus (P<0.05), and cortex (P<0.01).
Concerning MDA level, stressed animals, receiving the
highest dose of nicotine (0.5 mg/kg) exhibited significant
increase in MDA concentration in the whole brain
(P < 0.001) , cerebe l lum (P < 0.01) , h ippocampus
(P < 0.001), and cortex (P < 0.01) in comparison to
stressed saline group. The increase in MDA level of un-
stressed mice receiving nicotine at the dose of 0.5 mg/kg
(whole brain P < 0.001, hippocampus P < 0.001, cortex
P< 0.001) in comparison to unstressed saline group was
also observed. Moreover, nicotine at the dose of 0.1
increased MDA value in the cortex (P<0.001) as compared
with the unstressed saline-treated group.
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Discussion
Stress has been already defined as a non-specific response of
the body to any change, and has been associated with a greater
risk for different clinical conditions, including psychiatric dis-
orders, such as depression and anxiety [35]. To better study
the consequences of stress on behavior, animal models have
been developed including the CUMS procedure. Briefly, in
this model, rodents are exposed to a variety of relatively mild
neither controllable nor predictable stressors (i.e., restriction,
water/food deprivation, damp sawdust) intermittently, usually
for 3–4 weeks [8, 9, 11, 26]. Studies in animals have shown
that the CUMS model is able to evoke behavioral changes
resembling clinical depression symptoms, such as locomotor
activity impairment, reduced food or water consumption, and
a decrease in responsiveness to rewarding stimuli [36].
Nevertheless, results from studies testing anxiety- or
depression-related reactions induced by prior exposure to
stress are quite ambiguous. While some authors have reported
increases in anxiety and depression, others have found no
e f f e c t s o r e v en a d e c r e a s e i n anx i e t y and / o r
depression-related responses after exposure to different kinds
of stressors or to different models [26, 37, 38]. Possible ex-
planation for the different effects observed might rely on the
magnitude or kind of the stressor used.
The CUMS model presents good validity and has been
broadly used to investigate some of the physiological and
behavioral consequences of chronic stress [8, 9, 11, 26].
Thus, in the present study, animals were either unstressed or
exposed for 4 weeks to an unpredictable chronic mild stress
procedure and subsequently tested in the battery of behavioral
paradigms, including anxiety- or depression-related in the
EPM and FST tasks or cognitive effects in the PA paradigm.
In this context, our results revealed that CUMS-exposed
animals exhibited several behavioral alteration, resembling
the symptoms of anhedonia and chronic human depression,
anxiety disorders and the disturbances in memory forma-
tions, i.e., increased immobility time in the FST, decreased
percentage of the time spent on the open arms and the
percentage of open arm entries in the EPM test as well as
decreased IL value in the PA test in stressed mice as com-
pared to unstressed control.
It has been established that stress can produce behavioral
and metabolic changes in exposed organisms, which can re-
sult in somatic and mental disorders. However, the exact neu-
ronal mechanism behind the main effect of chronic stress ex-
posure is still to be elucidated. These diverse effects include
alterations of the catecholaminergic, opioidergic, serotonergic,
and steroid systems in the brain, and may contribute to its
pathophysiology [39, 40]. There has been very little research
examining the cholinergic mechanisms of the CUMS-induced
changes. Thus, increases in cholinesterase expression in the
hippocampus following CUMS have been reported, whereas
reductions in cholinesterase activity have been described in
the cortex, hypothalamus, and striatum (but not hippocampus)
[41]. Also, a paper has documented reductions in muscarinic
cholinergic receptors in the hippocampus and cortex, but not
hypothalamus [42]. Changes in cholinergic function follow-
ing CUMS may reflect changes in cognitive function from
stress and depression, but further work is required in this do-
main to understand further the influence of CUMS on the
cholinergic pathways. This is particularly important since
there is a body of evidence which has indicated that dysfunc-
tion of the cholinergic systemmay be present in major depres-
sion, such as impaired acetylcholinesterase activity or in-
creased activity at central nicotinic receptors [43]. In the con-
text of stress-induced behavioral changes and the influence of
cholinergic pathways, in the present study we demonstrated
memory impairment and depression- or anxiety-like behav-
iors induced by the CUMS, nicotine and their interactions in
mice. As such, nicotine, after an acute or repeated administra-
tion, reversed the depression-like and anxiogenic effects of the
CUMS in the FST and EPM, respectively, as well as memory
disturbances measured in the PA paradigm. Moreover, in the
FST, in stressed mice submitted to the CUMS protocol, sig-
nificant decrease in the antidepressant effects of nicotine has
been observed. In this animal model, metyrapone, a cortico-
sterone synthesis inhibitor, diminished the depression-like ef-
fect of stress suggesting the influence of glucocorticosteroids
and the HPA axis in stress-induced anhedonia.
Nicotine is the psychoactive substance responsible for the
addictive use of tobacco, which results in numerous harmful
health effects and continues to be the leading cause of prevent-
able death [44]. It has been reported that addicted tobacco
users suffer from nicotine-induced cognitive impairments, as
well as modulated mood such as anxiety- and depression-like
symptoms [45]. Furthermore, it has been suggested that brain
regions such as the medial prefrontal cortex, for which
nicotine-induced effects have been demonstrated, are concur-
rently involved in the development of stress-induced working
memory impairments and anxiety [46, 47]. However, there are
only few studies investigating the specific effects of nicotine
as a stressor, particularly those on cognitive function or
anhedonia-related mood disturbances [48]. In some rodent
models, CUMS or acute stress has been shown to aggravate
the behavioral and neuronal effects of nicotine [49]. However,
some antagonistic effects of subsequently administered nico-
tine against the behavioral (cognitive) and neuronal impair-
ments caused by stress have been reported in some rodent
models [50–52]. With respect to the interactions between nic-
otine, stress, and anhedonia-related syndromes, it has been
shown that both nicotine and CUMS enhanced each other’s
unfavorable effects on behavioral function including those on
the working memory- and anxiety-related behavioral alter-
ations in the Y-maze and EPM tests [53]. Therefore, the rela-
tionship between stressors such as the CUMS and nicotine
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remains controversial (i.e., antistress effects of nicotine have
also been reported depending on the conditions) [50].
It still remains controversial whether nicotine actually re-
duces stress in humans and animals. Thus, the regulatory path-
ways mediating behavioral and metabolic response to stress
and/or nicotine have not been clearly demonstrated so far. One
of the limiting factors is that the pattern of these changes
strongly depends on the kind of the stress stimulus. It is of
interest to understand the behavioral effects of nicotine that
might explain ongoing tobacco use, as it has been shown that
cigarette smoking can diminish anxiety and relieve stress in
humans, which are likely attributable to the nicotine as a psy-
choactive component of cigarette smoke [54]. The most strik-
ing feature of the recent study is that nicotine, after its chronic
administration, attenuates stress-induced decrease in locomo-
tor activity and in plasma amino acid concentrations [50, 55].
Numerous human studies have demonstrated an increase in
smoking rate among smokers exposed to stress, and such a
paradoxical behavior is believed to reduce the subjective feel-
ing of stress-related tension [15, 56]. At the same time, nico-
tine dependence may be associated with mood liability and
anxiety, leading to increased feelings of stress in many regular
smokers. Actually, smoking under stress lead smokers to
stress levels that are comparable to nonsmokers, suggesting
that acute nicotine withdrawal increases stress, and nicotine
reinstatement relieves feelings of stress [57].
Anxiety is thought to be a negative emotion caused by
many kinds of stress. In this field, the EPM task has become
one of the most popular animal paradigms also used in our
study. In this test, the anxiety-like behavior (i.e., decreased
percentage time spent in the open arms and open arms entries)
is potentiated by prior exposure to a variety of stressors [58],
as confirmed by our data. Nicotine has been shown to affect
anxiety in different ways in animal studies. In rodents, nico-
tine can be anxiolytic, anxiogenic, or have no effect on anxi-
ety, depending on the dose used, the route of administration,
the behavioral test performed and the time of testing after
nicotine administration [24, 30, 59, 60]. However, there is less
reports related to the effects of nicotine on stress-enhanced
anxiety [55]. Our study has demonstrated that nicotine admin-
istered acutely (at the active dose) or subchronically (at the
inactive dose), decreased the anxiety-like effects of stress in
mice after the CUMS protocol. Concerning depression-like
effects measured in the FST, also commonly used in rodents,
nicotine has been shown to provoke antidepressive action, i.e.,
decrease in immobilization time [61] also confirm in our study
in non-stressed mice. Similar to anxiety, our data revealed that
nicotine can diminish depression-like effects of chronic mild
stress. Moreover, in stressed mice submitted to the CUMS
protocol, significant decrease in the antidepressant effects of
nicotine by itself has been observed suggesting the reciprocal
influence of stress and nicotine. Although the precise mecha-
nism of such an effect is not clear, it can be speculated that it
involves nicotinic receptor-mediated modulation of the re-
sponses of the HPA axis to stress.
Concerning neuronal mechanisms of above-mentioned in-
teractions, differential pathways activation induced by stress
are reported in different studies, in terms of the nature of the
stress and the intensity of the stimulus [62, 63]. There is a
general agreement that both stressor stimuli and nicotine acti-
vate central nervous system [64–66]. Certain forebrain regions
seem to be pivotal in gating the stress-induced inputs to the
paraventricular nucleus of the hypothalamus (PVN). Medial
prefrontal cortex, central amygdala, bed nucleus of the stria
terminalis, and hippocampus, as major regulatory inputs to
the PVN, have been implicated in the induction of the en-
hanced anxiety state induced by stressors or anxiogenic drugs
[67–69]. In a recent paper, nicotine was shown to reduce the
restraint enhanced anxiety-like behaviors and also the
restraint-induced c-Fos expression in several brain regions im-
plicated in stress and anxiety [55]. In general, stress can pro-
duce an array of hormonal, autonomic, and behavioral re-
sponses. Moreover, chronic stress exposure and resulting dys-
regulation of the HPA axis develops susceptibility to variety of
neurological and psychiatric disorders including anxiety- and
depression or memory disturbances. Accordingly, it has been
reported that nicotine administration during restraint stress en-
hances the increase in plasma corticosterone, as compared to
the responses induced by either factor alone. On the contrary,
in one study the restraint-induced increase in plasma cortico-
sterone was not affected by nicotine [55]. The disparity of
nicotine’s effect on stress-induced responses indicates that
stress-induced anxiety-like behavior might be dissociated with
HPA axis activation. Considering this kind of dissociation be-
tween anxiety-like behavior and the HPA axis activation [70],
it is suggested that nicotine might selectively modify the neu-
ronal circuits related to behavioral changes rather than hormon-
al response to stress. This effect, which is independent on the
plasma levels of corticosterone, may be associated with the
reduction of above-mentioned stress-induced c-Fos expression
in certain brain regions involved in stress or anxiety rather than
affecting HPA axis hormone responses, as already stated.
In light of the data which have shown that nicotine can
diminish the memory impairment caused by a chronic stress,
it has been reported that modifications in working memory
(both ameliorations and impairments) can occur due to even
slight changes in prefrontal dopamine levels [71]. Stress also
activates two dopaminergic pathways, such as the mesolimbic
and mesocortical systems which are involved in the regulation
of adaptive processes. It is considered that experiencing
stressogenic situations change the metabolism and release of
dopamine in the mesolimbic system. Moreover, repeated ex-
posure to stress can change the ability to react to subsequent
stressors, leading to disturbances in the function of the
mesolimbic systemwhich is significantly related to the central
action of nicotine. Exposure to a single, unexpected, and
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uncontrolled aversive stimulus leads to inhibition of dopamine
release and disturbances in the reaction to rewarding and aver-
sive stimuli [72]. Therefore, the working memory-related be-
haviors in the nicotine-treated mice may be correlated with
alterations in nicotinic cholinergic receptor (nAChR)-mediated
prefrontal dopamine release, which is controlled by specific
nAChR subtypes (e.g., alpha7 nAChRs) [73]. In addition to
dopamine release, the release of other neurotransmitters such
as glutamate has been implicated in the nicotine-induced work-
ing memory formation [74]. In studies on mice or rats, it has
been proposed that acute or chronic stress disturbs
hippocampal-dependent memory formation [75] and reverses
long-term potentiation (LTP) induction, which is the basis of
synaptic plasticity and memory formation [76]. The dentate gy-
rus (DG) of the hippocampus shows pronounced functional and
morphological changes in response to the CUMS. Animals ex-
posed to stress display atrophy of CA3 pyramidal neurons, re-
duced neurogenesis in the DG, and alterations in hippocampal
apoptosis [77–79]. The increases in serum corticosterone ob-
served in animals submitted to the CUMS protocol corroborate
previous evidence [80], and suggest that, as already described,
chronic stress exposure effectively activates the HPA axis, what
is possibly responsible for the decreases in neuronal migration
observed in the hippocampus, as indicated by previous studies
[46, 80]. This effect can explain the memory dysfunction after
the CUMS protocol used in the current experiments. It is well
established that nicotine causes an above-stated increase in the
secretion of adrenocortiotropic hormone (ACTH) and cortico-
sterone in human and other animals [81]. Thus, mesolimbic
dopaminergic neurons possess corticosteroid receptors [82]
and there are functional changes in nAChRs and glucocorticoid
receptor in the brain. From this evidence and these results [83], it
can be speculated that functional changes in nAChRs and glu-
cocorticoid receptor in the brain may be induced by nicotine
treatment and/or psychological stress in terms of cognition and
anhedonia.
Taking into account our biochemical analysis, it has been
already described that the brain monoamine or cholinergic and
antioxidant defense systems interact closely with the HPA axis
and can be implicated in the acquisition and consolidation of
psychological and physical long-term stress responses [84, 85].
Chronic stress has been shown to increase the vulnerability of
different brain regions, particularly the hippocampus, by alter-
ing the antioxidant defense capacity. As already stated, stress is
an unavoidable life experience, and chronic stress has been
related with deregulation of many biological and physical pro-
cesses. Among them, increased oxidative stress within the cen-
tral nervous system could correlate with impairments in brain
function within behavior as well as control on other organs
[86]. Therefore, we examined the effects of CUMS on TAS
and key antioxidant enzymes of brain with special impact on
the structures involved in cognitive functions, e.g., prefrontal
cortex and hippocampus. Additionally, as SOD catalyzes
dismutation of superoxide into hydrogen peroxide and then
GPx catalyzes reduction of H2O2 into hydrogen and water,
their inappropriate effectiveness causes production of hydroxyl
radical (OH⋅). The radical is highly reactive although
short-lived. However, it plays a crucial role in the process of
lipids peroxidation. Stress has been well documented to induce
alterations in antioxidant barrier as well as promote oxidative
stress [87]. Our studies are along with those findings. We have
confirmed involvement of CUMS-provoked induction of oxi-
dative stress within brain and its particular structures as our
results have proven decrease in TAS in stressed mice, decrease
in antioxidant enzymes SOD and GPx as well as increase in
concentration of MDA.
Literature data show that nicotine provokes cognition-
enhancing and memory improving effects [21]. However, mo-
lecular studies prove that nicotine induces oxidative stress
within liver, kidneys, heart and brain of experimental animals
in vivo [88] and in vitro in cell cultures study [89]. The liver
and kidneys are associated with nicotine metabolism while
heart and brain are targeted organs of its action. The results
of our previous study support the thesis that an acute nicotine
treatment induces oxidative stress within brain structures
responsible for learning and memory processes [21]. These
experiments along with the present data showed significant
increase in concentration of MDA as well as suppression of
antioxidant enzymes (SOD and GPx) activities after nicotine
administration within all examined brain structures and in the
whole brain tissue, like in the case of CUMS in stressed ani-
mals. As such, the present study strongly confirmed
pro-oxidative effect of nicotine administered acutely and
subchronically and can prove that nicotine potentiates
cortisol-induced oxidative stress on the level of total antioxi-
dant status and antioxidant enzymes activity as well as in-
crease in peroxidation of lipids. People in stress often smoke
more as they feel more relaxed then. It is a strictly psycholog-
ical impression, because in fact nicotine activates HPA axis on
the stage of ACTH excretion and therefore increases the level
of cortisol liberated to blood stream [90]. Additionally, our
study further confirmed increase in oxidative stress parame-
ters after acute as well as subchronic nicotine administration in
stressed mice submitted to the CUMS protocol, i.e., decreased
TAS, SOD, and GPx activity and increased MDA concentra-
tion. It is worth noting that several studies suggested
that different results in antioxidant barrier status of tissues
of animals’ exposure to chronic stress and/or nicotine may
come from differences in protocols used for the induction
of stress (different type of stress) as well as the applied
animal model [17].
To sum up, acute or chronic stress is one of the most val-
idated animal models for generating the depression-like symp-
toms observed in humans [91]. Animal models of CUMS
represent valuable tools to investigate the behavioral, endo-
crine, and neurobiological changes underlying stress-related
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psychopathologies, such as anhedonia and memory distur-
bances, a core endophenotype of human depression. The pres-
ent study was aimed at investigating the anxiety- and
depression-related action as well as cognitive disturbances in
mice exposed to the chronic stress model. To this purpose,
mice were subjected to 4 weeks of chronic unpredictable
stressful stimuli, after which the animals were submitted to a
behavioral test, i.e., the FST, EPM and PA paradigm. Nicotine,
after an acute and subchronic administration decreased
stress-induced depression- and anxiety-like effect as well as
memory deficit in mice indicating the relationship between
stress and nicotine. Our study contributes to the understanding
of the mechanisms that are possibly involved in the biological
basis of central stress-induced disorders such as anxiety, de-
pression, and other neurodegenerative conditions including
memory disturbances. The present findings also support the
hypothesis that neurotransmitter intervention in oxidative
damage should be considered as a possible mechanism of
pro-oxidative stress- or nicotine-induced alterations; however,
understanding of its precise mechanisms warrants further
studies required to explore these integrated dual mechanisms
operating during stressful conditions.
Thus, elucidating howmonoaminergic and cholinergic sys-
tems interact with one another during the development of
anhedonia-like states will increase our knowledge of the path-
ogenesis of the disease and nicotine-stress interactions on the
basis of the development of nicotine dependence and ongoing
tobacco abuse.
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